目的 探讨保妇康栓联合氟罗沙星胶囊治疗慢性盆腔炎的临床疗效。方法 选取2022年4月—2023年9月在北京市第六医院就诊的92例慢性盆腔炎患者，按照随机数字表法将患者分为对照组和治疗组，每组各46例。对照组口服氟罗沙星胶囊，2粒/次，2次/d。治疗组在对照组基础上使用保妇康栓治疗，外阴部洗净后将保妇康栓推入阴道深处，1粒/次，每晚1次。7 d为1个疗程，两组患者共治疗2个疗程。比较两组的治疗效果、症状缓解时间、超声指标、血液流变学和血清指标。结果 治疗后，治疗组的总有效率为93.48%，对照组的总有效率为78.26%，组间比较差异有统计学意义（P＜0.05）。治疗后，治疗组腰骶疼痛、下腹痛、白带量多、神疲乏力缓解时间明显短于对照组，差异有统计学意义（P＜0.05）。治疗后，两组的炎性包块最大直径、盆腔积液量比治疗前小（P＜0.05）；治疗组的炎性包块最大直径、盆腔积液量比对照组小（P＜0.05）。治疗后，两组的血浆黏度、血沉、纤维蛋白原比治疗前小（P＜0.05）；治疗组的血浆黏度、血沉、纤维蛋白原均比对照组小（P＜0.05）。治疗后，两组的血清白细胞介素-2（IL-2）水平比治疗前升高，血清单核细胞趋化蛋白-1（MCP-1）、肿瘤坏死因子-α（TNF-α）水平比治疗前降低（P＜0.05）；治疗组的血清IL-2水平比对照组高，血清MCP-1、TNF-α水平比对照组低（P＜0.05）。结论 保妇康栓联合氟罗沙星胶囊可提高慢性盆腔炎的治疗效果，缩小炎性包块，改善血液流变学水平，减轻炎症反应。

Objective To investigate the clinical effect of Baofukang Suppository combined with Fleroxacin Capsules in treatment of chronic pelvic inflammatory disease. Methods Patients (92 cases) with chronic pelvic inflammatory disease in Beijing Sixth Hospital from April 2022 to September 2023 were divided into control and treatment groups according to the random number method, and each group had 46 cases. Patients in the control group were po administered with Fleroxacin Capsules, 2 grains/time, twice daily. Patients in the treatment group were given with Baofukang Suppository on the basis of the control group, after washing the external genitalia, pushing the Baofukang Suppository deep into the vagina, once daily. One course of treatment had 7 days, and patients in two groups were treated for 2 courses. After treatment, the clinical efficacies, the symptom relief time, ultrasound indicators, hemorheology, and serum indicators in two groups were compared. Results After treatment, the total effective rate of the treatment group was 93.48%, while the total effective rate of the control group was 78.26%, and the difference between the groups was statistically significant (P < 0.05). After treatment, the relief time for lumbosacral pain, lower abdominal pain, excessive vaginal discharge, and fatigue in the treatment group was significantly shorter than that in the control group, and the difference was statistically significant (P< 0.05). After treatment, the maximum diameter of inflammatory masses and pelvic fluid accumulation in two groups were smaller than before treatment (P< 0.05), and the maximum diameter of inflammatory masses and pelvic fluid accumulation in the treatment group were smaller than those in the control group (P < 0.05). After treatment, the plasma viscosity, erythrocyte sedimentation rate, and fibrinogen in two groups were lower than before treatment (P < 0.05), and the plasma viscosity, erythrocyte sedimentation rate, and fibrinogen in the treatment group were all lower than those in the control group (P < 0.05). After treatment, the serum levels of IL-2 were higher than before treatment, but the serum levels of MCP-1 and TNF-α were lower than before treatment (P < 0.05). After treatment, the serum levels of IL-2 in the treatment group was higher than that in the control group, but the serum levels of MCP-1 and TNF-α were lower than those in the control group (P < 0.05). Conclusion Baofukang Suppository combined with Fleroxacin Capsules can further improve the therapeutic effect of chronic pelvic inflammatory disease, further reduce inflammatory mass, improve hemorheology level, and reduce inflammatory response.

R984